Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
Want to see CPIX full AI Analyst Report?
Top Page
Cumberland Pharmaceuticals
(NASDAQ:CPIX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$5.50
▲(16.53% Upside)
Action:Reiterated
Date:05/09/26
The score reflects weak underlying financial performance (ongoing losses and deteriorating TTM margins) balanced by a constructive strategic outlook from the Apotex transaction and solid near-term technical momentum. Valuation is constrained by negative earnings and no dividend support, while the earnings call improves the outlook but remains contingent on successful deal close and execution.
Positive Factors
High Gross Margins
Sustained gross margins near 83–85% indicate durable product-level profitability and pricing power in Cumberland’s commercial portfolio. High product margins provide cushion to fund R&D and pipeline work even as overall operating leverage is rebuilt after the strategic sale.
Negative Factors
Persistent Net Losses
Widening TTM losses and negative ROE reflect weak operating leverage and persistent profitability gaps. Continued net losses can erode equity and limit ability to self‑fund development activities absent transaction proceeds or new financing, raising medium‑term execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained gross margins near 83–85% indicate durable product-level profitability and pricing power in Cumberland’s commercial portfolio. High product margins provide cushion to fund R&D and pipeline work even as overall operating leverage is rebuilt after the strategic sale.
Read all positive factors
Cumberland Pharmaceuticals Key Performance Indicators (KPIs)
Any
Net Revenue by Product
Breaks down sales by individual drug or product, showing which items drive total revenue and how dependent the company is on a few offerings. For Cumberland Pharmaceuticals, product-level revenue highlights concentration risk, the effect of pricing or reimbursement shifts, and whether new launches or partnerships are expanding the business and supporting sustainable growth.
Breaks down sales by individual drug or product, showing which items drive total revenue and how dependent the company is on a few offerings. For Cumberland Pharmaceuticals, product-level revenue highlights concentration risk, the effect of pricing or reimbursement shifts, and whether new launches or partnerships are expanding the business and supporting sustainable growth.
Data provided by:
The Fly
The FlyCumberland Pharmaceuticals (CPIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$76.71M
Dividend YieldN/A
Average Volume (3M)27.29K
Price to Earnings (P/E)―
Beta (1Y)0.07
Revenue Growth2.08%
EPS Growth-106.57%
CountryUS
Employees91
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.49
Shares Outstanding14,983,107
10 Day Avg. Volume30,352
30 Day Avg. Volume27,288
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.39
Price to Sales (P/S)1.34
P/FCF Ratio12.31
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit2.36
Enterprise Value/Ebitda-43.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cumberland Pharmaceuticals Business Overview & Revenue Model
Company Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States...
How the Company Makes Money
Cumberland primarily makes money by selling its branded prescription pharmaceuticals. Revenue is generated from product sales to customers such as wholesalers and distributors (and, depending on the product and channel, hospitals, specialty pharma...
Cumberland Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call highlights meaningful strategic progress: a transformational $100M acquisition agreement that unlocks near-term value, regulatory wins (expanded Caldolor label and facility clearance), commercialization progress (Talicia promotion, Vibativ China shipment) and an encouraging development pipeline (ifetroban with Fast Track and robust safety data). These positives are tempered by a modest Q1 revenue base, a GAAP net loss (~$3.3M) and limited cash on hand until the transaction closes, plus the company’s deliberate pivot away from pursuing double-digit revenue growth in 2026. On balance, the call emphasizes value realization and a clear strategic plan to focus on development, with the transaction expected to materially strengthen the balance sheet and reduce operating expense burden—leading to a favorable overall tone.Positive Updates
Transformational Strategic Transaction with Apotex
Apotex will acquire Cumberland's marketed U.S. commercial portfolio for $100 million in cash at closing, plus $9 million for inventory, transition service fees and a future sales-tied milestone — a transaction management expects will materially strengthen the balance sheet and unlock near-term shareholder value.
Negative Updates
Net Loss and Operating Expense Pressure
Q1 operating expenses were $12.3 million, producing a GAAP net loss of approximately $3.3 million. After adding back noncash items, adjusted loss was $1.9 million, or $0.13 per share.
Read all updates
Q1-2026 Updates
Positive
Negative
Transformational Strategic Transaction with Apotex
Apotex will acquire Cumberland's marketed U.S. commercial portfolio for $100 million in cash at closing, plus $9 million for inventory, transition service fees and a future sales-tied milestone — a transaction management expects will materially strengthen the balance sheet and unlock near-term shareholder value.
Read all positive updates
Company Guidance
Management guided that, given the announced strategic transaction with Apotex, Cumberland is no longer targeting double‑digit revenue growth for 2026 and expects materially lower operating expenses after closing because Apotex will assume sales, marketing, medical, manufacturing and FDA fees; at closing Cumberland expects $100 million cash (subject to shareholder approval), $9 million for inventory, ongoing monthly transition service fees and future milestone payments. For context, Q1 combined brand revenue was $9.1 million (Kristalose $1.0M; Sancuso $2.9M; Vibativ $2.1M; Caldolor $1.0M; Talicia $1.9M), total operating expenses were $12.3M, net loss was about $3.3M, adjusted loss was $1.9M or $0.13 per share, cash flow from operations was $0.387M, total assets were $71M (cash $11M), liabilities $49.7M (including $5M credit facility) and shareholders’ equity $21.6M. Management also said 2026 clinical spending is expected to remain essentially unchanged, noted over $53M of tax net operating losses versus a $30M tax basis in the assets (supporting modest taxes on the deal), and highlighted pipeline progress (ifetroban dosed in ~1,400 subjects, Fast Track/orphan/rare pediatric designations) and product milestones such as FDA‑expanded Caldolor labeling and a Vaprisol relaunch expected this year.Cumberland Pharmaceuticals Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
56
Neutral
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.94M | 44.52M | 37.87M | 39.55M | 42.01M | 35.99M |
| Gross Profit | 34.76M | 37.85M | 31.28M | 33.49M | 32.89M | 27.17M |
| EBITDA | -1.90M | 2.49M | 182.42K | 2.49M | 332.92K | -857.83K |
| Net Income | -7.23M | -2.84M | -6.48M | -6.28M | -5.57M | -3.51M |
Balance Sheet | ||||||
| Total Assets | 71.00M | 76.82M | 75.58M | 81.78M | 92.93M | 84.46M |
| Cash, Cash Equivalents and Short-Term Investments | 11.01M | 11.44M | 17.96M | 18.32M | 19.76M | 27.04M |
| Total Debt | 10.07M | 10.18M | 20.57M | 18.43M | 20.96M | 16.06M |
| Total Liabilities | 49.69M | 52.28M | 53.04M | 52.52M | 56.95M | 41.86M |
| Stockholders Equity | 21.64M | 24.88M | 22.85M | 29.60M | 36.27M | 42.81M |
Cash Flow | ||||||
| Free Cash Flow | 1.33M | 4.83M | -791.90K | 5.64M | 6.38M | 5.99M |
| Operating Cash Flow | 1.42M | 4.93M | -612.19K | 6.09M | 8.45M | 6.34M |
| Investing Cash Flow | -3.54M | -4.71M | 57.84K | -105.69K | -13.67M | -501.89K |
| Financing Cash Flow | -1.98M | -6.75M | 196.90K | -7.42M | -2.06M | -3.55M |
Cumberland Pharmaceuticals Technical Analysis
Positive
4.72
Price Trends
3.65
Positive
3.89
Positive
3.46
Positive
Market Momentum
0.45
Negative
71.51
Negative
86.47
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPIX, the sentiment is Positive. The current price of 4.72 is above the 20-day moving average (MA) of 4.48, above the 50-day MA of 3.65, and above the 200-day MA of 3.46, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 71.51 is Negative, neither overbought nor oversold. The STOCH value of 86.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CPIX.
Cumberland Pharmaceuticals Risk Analysis
Cumberland Pharmaceuticals disclosed 1 risk factors in its most recent earnings report. Cumberland Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cumberland Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $76.71M | -3.87 | -28.75% | ― | 2.08% | -106.57% | |
53 Neutral | $150.70M | -1.63 | -38.72% | ― | -14.15% | -15.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $52.96M | -4.80 | -190.00% | ― | -100.00% | 54.21% | |
49 Neutral | $30.84M | >-0.01 | -4587.82% | ― | -30.75% | -1056.69% | |
49 Neutral | $54.43M | -0.55 | -57.16% | ― | 673.54% | 23.14% | |
41 Neutral | $50.38M | -15.84 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
CPIX
Cumberland Pharmaceuticals
5.53
0.57
11.49%
ASRT
Assertio Therapeutics
23.44
13.15
127.79%
RMTI
Rockwell Med
0.82
-0.18
-17.59%
SCYX
SCYNEXIS
0.67
-0.10
-13.38%
KALA
KALA BIO
2.65
-185.85
-98.59%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.71
-3.07
-45.27%
Cumberland Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Cumberland Shareholders Back Board, Auditor and Pay Policies
Positive
Apr 24, 2026
At Cumberland Pharmaceuticals Inc.’s annual shareholder meeting held on April 21, 2026, in Nashville, Tennessee, investors elected Class I directors Kenneth J. Krogulski and Caroline R. Young with over 98% of votes cast in favor, underscorin...
Business Operations and StrategyM&A Transactions
Cumberland Divests Branded Assets, Refocuses on Orphan Drugs
Positive
Apr 23, 2026
On April 22, 2026, Cumberland Pharmaceuticals entered into a $100 million asset sale with an affiliate of Apotex to integrate its U.S. branded commercial business into Apotex’s new U.S. platform for specialty medicines. Apotex will acquire C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.